Pharma and healthcare stocks in focus as Akums rolled out pain therapy, Ind-Swift secured EU-GMP certification, Zydus-owned Sentynl advanced Menkes drug review, Senores bought Apnar Pharma, and KIMS commissioned a new Bengaluru hospital facility.
| Photo Credit:
Akums Drugs & Pharmaceuticals Ltd has announced the rollout of its enhanced Gabapentin Extended-Release (ER) formulation for the management of Postherpetic Neuralgia (PHN). PHN, a chronic neuropathic pain condition that can persist for months after a shingles outbreak, affects nearly 10-20 per cent of patients and becomes increasingly debilitating with age. Many individuals experience constant burning or throbbing discomfort, sudden shooting pain, or allodynia-symptoms that severely impact mobility, sleep, and emotional well-being.
The Global Business Unit (Formulations Facility) of Ind-Swift Laboratories Limited at Jawaharpur, Derabassi, Punjab, has received a certificate of GMP compliance from the National Center for Public Health and Pharmacy (NNGYK-Hungary) following an EUDRA GMP inspection conducted in November 2025. The said certificate is valid for 3 (Three) years and opens the European and other markets to the Company’s products. The global business unit already holds certifications from WHO-GMP, TGA (Australia), MHRA (UK), SAPRA (South Africa), and EU-GMP.
Sentynl Therapeutics, Inc., a US-based biopharmaceutical company wholly owned by Zydus Lifesciences, Ltd, has announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application for copper histidinate (CUTX-101), intended to treat Menkes disease in pediatric patients. The resubmission has been accepted as a Class I response, and as a result, the Company has received January 14, 2026, as the new PDUFA date.
Senores Pharmaceuticals informed the bourses about a strategic acquisition that will expand its pharmaceutical manufacturing capabilities. It has announced the acquisition of a 100% stake in Apnar Pharma Private Limited for a total enterprise value of ₹91.00 crore. Its board has approved the acquisition of Apnar Pharma Private Limited on December 15, 2025, marking a significant step in the company’s growth strategy.
KIMS Hospital Bengaluru Private Limited, a subsidiary of Krishna Institute of Medical Sciences Limited, has formally commenced operations at its newly established hospital located at PES University campus in Electronic City, Bengaluru. The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital, offering advanced care in Cardiac, Neuro, Oncology, Organ Transplant, & Robotic Sciences, with cutting-edge tech, experienced specialists, and a focus on patient comfort and quality care, featuring modern infrastructure and a 24/7 emergency catering to critical and routine healthcare needs.
Published on December 16, 2025